<DOC>
	<DOCNO>NCT00003418</DOCNO>
	<brief_summary>RATIONALE : Estrogen stimulate growth breast cancer cell . Hormone therapy use exemestane tamoxifen may fight breast cancer block uptake estrogen . It yet know whether exemestane effective tamoxifen treat breast cancer . PURPOSE : Randomized phase III trial compare effectiveness exemestane tamoxifen treat postmenopausal woman primary breast cancer already receive 2-3 year tamoxifen follow surgery .</brief_summary>
	<brief_title>Exemestane Compared With Tamoxifen Treating Postmenopausal Women With Primary Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare , term disease-free survival overall survival , sequential administration exemestane administration tamoxifen 5 year therapy achieve postmenopausal woman operable breast cancer already receive 2-3 year adjuvant tamoxifen . II . Compare regimens term incidence contralateral breast cancer long term tolerability regimens patient . III . Determine tolerability regimen term endometrial status , bone metabolism , lipid profile , coagulation profile patient . IV . Assess quality life patient treat regimen . OUTLINE : This randomize , double blind , multicenter study . Following 2-3 year adjuvant treatment tamoxifen , patient randomize receive either oral tamoxifen daily oral exemestane daily remainder 5 year period absence disease relapse unacceptable toxicity . Quality life assess center . Patients follow least every 3 month first year treatment , every 6 month next two year annually thereafter year 10 . PROJECTED ACCRUAL : Approximately 4400 patient ( 2200 patient arm ) accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : At diagnosis : Histologically confirm unilateral adenocarcinoma breast consider operable Must adequate therapy primary disease include chemotherapy/ovarian ablation appropriate local postoperative radiotherapy patient receive conservative ( breast preserve ) surgery Must remain diseasefree therapy primary disease Must receive tamoxifen minimum 2 year maximum 3 year 1 month 1 month break one time No inflammatory breast cancer , histologically positive supraclavicular node , ulceration/infiltration skin metastases No evidence local relapse distant metastasis ( chest xray , scintigraphic bone scan liver ultrasonography/CT scan ) time Hormone receptor status : Estrogen receptor positive unknown PATIENT CHARACTERISTICS : Age : Postmenopausal define Sex : Female Menopausal status : Postmenopausal define : 55 year age , amenorrhea great 2 year OR Radiation menopause ( least 3 month previously ) surgical oophorectomy OR Natural amenorrhea least 1 year breast cancer diagnosis Performance status : Not specify Life expectancy : Not specify Hematopoietic : WBC least 4,000/mm3 Hemoglobin normal Hepatic : SGOT great 2.5 time upper limit normal ( ULN ) Renal : Creatinine great 1.5 time ULN Cardiovascular : No significant cardiac disorder Other : No significant skeletal endocrine disorder No clinical evidence severe osteoporosis and/or history osteoporotic fracture No prior malignancy except basal cell skin cancer carcinoma situ cervix No psychiatric addictive disorder PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Prior concurrent bisphosphonates allow Adjuvant neoadjuvant chemotherapy primary disease allow Endocrine therapy : At least 4 week since prior hormone replacement therapy ( oral , topical , vaginal ) Prior lowdose progestin relief menopausal symptom ( 6 month duration ) allow No concurrent progestins No concurrent systemic corticosteroid prolong period ( i.e. , great 2 week ) No concurrent selective estrogen receptor modulators Radiotherapy : See Disease Characteristics Surgery : See Disease Characteristics Other : Prior participation completion therapy another clinical study systemic therapy ( e.g. , comparison chemotherapy schedule ) allow No concurrent warfarin Concurrent treatment disease allow clinically indicate</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage III breast cancer</keyword>
</DOC>